BridgeMD
Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: The CANIQOL multicentre study
EU CTIS ID: 2024-518991-30-00
What this study is testing
To evaluate the impact of digital monitoring of self-reported symptoms (PROs-CTC-AEs) to adjust treatments management of patients treated with cabozantinib plus nivolumab for advanced clear-cell RCC in real life during the first 3 months of the combined treatment
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient older than 18 years
- Diagnosis of Renal Cell Carcinoma (RCC) with a clear-cell component
- No prior systemic treatment for RCC
- Physician-initiated decision prior to study enrollment to treat with cabozantinib and nivolumab in combination, according to approved local labels
- Subjects affiliated to an appropriate social security system
- Patient has signed informed consents obtained before any trial related activities and according to local guidelines
You likely can't join if
- Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
- Current participation in another clinical study and/or in an investigational program with any intervention that could possibly interfere with the treatment and impact this study
- Patient with history of allergy or hypersensitivity to components of the study drugs
- Patient with contraindication to the study drugs
- Pregnant or lactating woman
- Patient unable to use digital tools
See the full eligibility criteria
- Patient older than 18 years
- Diagnosis of Renal Cell Carcinoma (RCC) with a clear-cell component
- No prior systemic treatment for RCC
- Physician-initiated decision prior to study enrollment to treat with cabozantinib and nivolumab in combination, according to approved local labels
- Subjects affiliated to an appropriate social security system
- Patient has signed informed consents obtained before any trial related activities and according to local guidelines
- Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
- Current participation in another clinical study and/or in an investigational program with any intervention that could possibly interfere with the treatment and impact this study
- Patient with history of allergy or hypersensitivity to components of the study drugs
- Patient with contraindication to the study drugs
- Pregnant or lactating woman
- Patient unable to use digital tools
- Patient deprived of liberty or placed under the authority of a tutor
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.